Business Description
Galectin Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US3632252025
Total Employee Number:
9Description
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.1 | |||||
Equity-to-Asset | -8.26 | |||||
Debt-to-Equity | -1.04 | |||||
Debt-to-EBITDA | -7.29 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 16.7 | |||||
3-Year EPS without NRI Growth Rate | 13.7 | |||||
3-Year FCF Growth Rate | 10.6 | |||||
3-Year Book Growth Rate | -50.4 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 33.58 | |||||
9-Day RSI | 48.38 | |||||
14-Day RSI | 54.82 | |||||
3-1 Month Momentum % | 13.81 | |||||
6-1 Month Momentum % | -19.53 | |||||
12-1 Month Momentum % | 0.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.15 | |||||
Quick Ratio | 2.15 | |||||
Cash Ratio | 1.93 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.1 | |||||
Shareholder Yield % | -9.35 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -179.1 | |||||
ROIC % | -35.6 | |||||
3-Year ROIIC % | -3193.53 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -20.94 | |||||
EV-to-Forward-EBIT | -18.9 | |||||
EV-to-EBITDA | -21.01 | |||||
EV-to-Forward-EBITDA | -18.9 | |||||
EV-to-Forward-Revenue | 4.03 | |||||
EV-to-FCF | -19.51 | |||||
Earnings Yield (Greenblatt) % | -4.78 | |||||
FCF Yield % | -7.5 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Galectin Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.352 | ||
| Beta | -0.0537 | ||
| 3-Year Sharpe Ratio | 0.83 | ||
| 3-Year Sortino Ratio | 1.77 | ||
| Volatility % | 144.8 | ||
| 14-Day RSI | 54.82 | ||
| 14-Day ATR (€) | 0.218229 | ||
| 20-Day SMA (€) | 3.274 | ||
| 12-1 Month Momentum % | 0.98 | ||
| 52-Week Range (€) | 1.61 - 5.8 | ||
| Shares Outstanding (Mil) | 65.86 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Galectin Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Galectin Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-03 11:00 | In 145 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 124 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 33 days | ||
| First quarter earnings results for 2026 | 2026-05-15 | 1.88 (+0.00%) | ||
| Annual report for 2025 | 2026-03-31 | 2.12 (-7.83%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-31 | 2.12 (-7.83%) | ||
| Galectin Therapeutics to Host Virtual KOL Event | 2026-03-10 12:00 | 2.66 (+1.53%) | ||
| General meeting for 2025 | 2025-12-03 11:00 | 4.54 (-2.99%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 4.56 (-8.43%) | ||
| H.C. Wainwright 9th Annual MASH Investor Conference | 2025-10-21 07:00 | 4.18 (-1.42%) |
Show
Entries
Galectin Therapeutics Inc Frequently Asked Questions
What is Galectin Therapeutics Inc(FRA:PHPN)'s stock price today?
The current price of FRA:PHPN is €3.40. The 52 week high of FRA:PHPN is €5.80 and 52 week low is €1.61.
When is next earnings date of Galectin Therapeutics Inc(FRA:PHPN)?
The next earnings date of Galectin Therapeutics Inc(FRA:PHPN) is 2026-08-14 Est..
Does Galectin Therapeutics Inc(FRA:PHPN) pay dividends? If so, how much?
Galectin Therapeutics Inc(FRA:PHPN) does not pay dividend.
Press Release
Articles on Galectin Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers